Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First In Human, Multi-Center Open-Label Randomized Trial to Assess Safety of Rincell-1 Otic Neural Progenitor Cell-Based Therapy and Standard Care vs Standard Care Alone, in Adults With Neural Hearing Loss Eligible for Cochlear Implantation

NCT07032038 is registered in ClinicalTrials.gov with Rinri Therapeutics as lead sponsor.

NCT NCT07032038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07032038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First In Human, Multi-Center Open-Label Randomized Trial to Assess Safety of Rincell-1 Otic Neural Progenitor Cell-Based Therapy and Standard Care vs Standard Care Alone, in Adults With Neural Hearing Loss Eligible for Cochlear Implantation
Lead sponsor
Rinri Therapeutics
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 30, 2027
Completion date
August 31, 2029
Enrollment
20 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

auditory neuropathy, presbyacusis, sensorineural hearing loss